Format

Send to

Choose Destination
Pharmacotherapy. 2001 Feb;21(2):142-8.

Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.

Author information

1
Department of Pharmacy Services, Detroit Receiving Hospital, Wayne State University, Michigan 48201, USA.

Abstract

STUDY OBJECTIVE:

To evaluate epidemiology, resistance, and treatment outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam for 72 hours or longer.

DESIGN:

Retrospective analysis.

SETTING:

University teaching hospital.

PATIENTS:

Forty-eight patients with A. baumannii bacteremia.

INTERVENTION:

Evaluation of susceptibility and clinical data from 48 patients treated with either ampicillin-sulbactam or imipenem-cilastatin from 1987-1999.

MEASUREMENTS AND MAIN RESULTS:

Comparing ampicillin-sulbactam and imipenem-cilastatin, there were no differences between days of bacteremia (4 vs 2 days, p=0.05), days to resolution of temperature or white blood cell count, success or failure during or at end of treatment, or intensive care unit total or antibiotic-related length of stay (13 vs 10 days, p=0.05). Patients treated with ampicillin-sulbactam had significantly decreased antibiotic treatment costs (1500 dollars vs 500 dollars, p=0.004).

CONCLUSION:

Ampicillin-sulbactam is at least as effective as imipenem-cilastatin based on clinical response at days 2, 7, and end of treatment and is a cost-effective alternative for treatment of A. baumannii infections.

PMID:
11213849
DOI:
10.1592/phco.21.2.142.34114
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center